Evexia Lifecare (524444)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 16.31% shows some top-line momentum
• Piotroski F-score of 7/9 indicates short-term financial health
• Price-to-book of 1.88 is not extreme for a small-cap
• Trading near 52-week high suggests strong market momentum

Concerns

• P/E of 176 with latest quarter net profit of ₹0 Cr indicates negligible real earnings
• ROE of 0.28% and ROCE of 0.30% destroy shareholder value
• Zero dividend yield forces complete reliance on share price appreciation
• Promoter holding undisclosed raises governance and trust questions

AI Analysis

Let me be candid: this is exactly the kind of stock that gets a value investor's pulse racing for all the wrong reasons. At ₹2.91, Evexia Lifecare trades at 176 times earnings, yet its return on equity is a paltry 0.28% and ROCE just 0.30%. If you handed me this business today, it earns almost nothing on the capital employed. The latest quarter tells the real story – ₹25 crore of sales, but net profit of precisely zero. That is not a business; it is a turnover story. The profit growth of 141.67% sounds impressive, but from a base of effectively nothing, any jitter in the numbers looks enormous. The sales growth of 16.31% is respectable, but for a chemical trader, that is hardly a moat. Book value per share is ₹1.55, so the market is paying nearly 1.9 times for a business earning 0.28% on that equity. The price has already run up from ₹0.47 to ₹2.91 – a six-fold jump – and even a generous PEG of 2.23 suggests the price has run far ahead of fundamentals. The Piotroski F-score of 7/9 shows some improving fundamentals, but for a pure trading business with no pricing power, that can reverse quickly. No dividend means we are relying entirely on price appreciation from other buyers – a greater fool theory. With promoter holding not disclosed, I have no assurance that those running the show have skin in the game. This is not investing; it is speculation. I would need a far lower price, evidence of sustainable margins, and serious capital allocation discipline before I would even look closer.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer